Current Concepts in Pancreatic Cancer by Ramzan, Zeeshan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Provisional chapter
Current Concepts in Pancreatic Cancer
Zeeshan Ramzan, Phat Le, Payal Kapur and
Sergio Huerta
Additional information is available at the end of the chapter
1. Introduction
Pancreatic cancer is one of the most lethal malignancies, ranking as the fourth leading cause
of death from cancer in the United States. Despite a variety of improved diagnostic and
therapeutic approaches over the past several decades the mortality rate has not significantly
improved. There is wide variation in the therapeutic approach to pancreatic cancer based upon
multiple factors such as the stage at presentation, patient’s coexisting medical comorbidities,
etc. and at times the optimal treatment strategy is still controversial.
2. Epidemiology
Cancer of the exocrine pancreas was diagnosed in 45,220 patients in the United States in 2013.
Underscoring its fatal nature, during the same year, 85% of patients (38,460) died from this
disease [2]. Thus, despite only comprising 3% of all new cancer diagnoses, pancreatic cancer
accounted for 6-7% of all deaths related to cancer [2]. Over the past 10 years, the similar
incidence and the death rates emphasize that most pancreatic cancers are fatal as a result of
late stage at diagnosis (Figure 1) [2-12]. Although, the gap between the yearly incidence and
mortality of pancreatic cancer has slightly widened over the past ten years, most patients
diagnosed with cancer will succumb to this deadly disease (Figure 2).
The average age at diagnosis is 60 to 65 years. The etiology of pancreatic cancer is not known,
but several risk factors have been identified. For instance, men have a slightly higher incidence
compared to women (Relative Risk [RR] 1.35) and Black men have a 30-40% higher rate in
incidence compared to White men [13]. Cigarette smoking is the best well-recognized envi‐
ronmental risk factor for the development of pancreatic cancer. Current smokers have a RR of
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up to 3.6 compared to non-smokers and smoking is estimated to contribute to 25% as an
etiology of pancreatic cancer [14;15]. Other risk factors for pancreatic cancer include: diabetes,
obesity, Helicobacter pylori infection, non-O blood group and chronic pancreatitis [16-20].
Most forms of pancreatic cancer are sporadic. However, familial pancreatic cancer accounts
for 5-10% of all pancreatic cancers [21]. Data from the National Familial Tumor Registry
demonstrates that the risk of pancreatic cancer of the pancreas is 18-fold higher if two first-
degree relatives are involved and 57-fold higher if three first-degree family members are
affected [22]. This risk is conferred by an increased risk in several recognized genetic syn‐
dromes caused by germline mutations leading to familial syndromes. For instance Peutz-
Jeghers Syndrome results from a germline mutation of the STK11 gene. Affected individuals
have a 132-fold increased risk for pancreatic cancer [23]. Familial Atypical Mole Multiple
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Figure 1. Incidence of Adenocarcinoma of the pancreas in the United States over the past ten years.
 
 
  
Figure 2. The incidence divided by the mortality in the Unites States over the past.
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Melanoma Syndrome patients with a germline mutation of the CDKN2A gene have a 46-fold
increased risk for the development of pancreatic cancer. Individuals with mutations of the
PRSS1 gene have an increase in trypsin activity, which in turn causes chronic inflammation of
the pancreas. These patients suffer from hereditary pancreatitis and have a 50-fold increase
risk of pancreatic cancer [23]. Other genetic syndromes that confer a higher risk include cystic
fibrosis (CTFR gene mutation), Fanconi Anemia, familial breast or ovarian cancer (BRCA2 gene
mutations), familial adenomatous polyposis (APC gene mutations), Li-Fraumeni syndrome
(p53 gene mutation) and Lynch II syndrome (MLH1 gene mutation) [24].
3. Pathology
Pancreatic ductal carcinomas arising from the exocrine pancreas is the most common type
accounting for 95% of these tumors. Two- thirds of these tumors occur in the head of the pancreas
and have an aggressive behavior [25]. The vast majority of malignancies of the pancreas are
infiltrating ductal adenocarcinomas and the term pancreatic cancer generally refers to adeno‐
carcinoma of the pancreas. Pancreatic cancer can originate from each of the cell types that form
the pancreas. For instance, neuroendocrine tumors arise from the pancreatic islet cells. Unlike
ductal adenocarcinoma, many of the endocrine tumors are benign. Small subsets are endo‐
crine carcinomas and make up around 1% of pancreatic cancers. Pancreatic cystic neoplasms
include a group of tumors having varying malignant potential. Uncommonly, extrapancreat‐
ic tumors can metastasize to the pancreas and have been reported from renal cell carcinoma,
non-small cell lung cancer, sarcoma, melanoma, and bladder cancers (Figure 3) [26].
Figure 3. Incidence of malignancies of the pancreas.
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Current pancreatic cancer models are similar to that of colon cancer, in which there is a
progression from precancerous lesions to invasive carcinomas. Pancreatic cancer evolves from
normal ductal epithelium, to pancreatic intraepithelial neoplasms/ductal lesions, to invasive
adenocarcinomas [27;28]. The ductal epithelium undergoes changes that are characterized by
PanIN-1A. Changes continue to accumulate and lead to PanIN-3, which denotes carcinoma in
situ (Figure 4). This evolution is associated with the acquisition of a large number of genetic
alterations that function through a small number of signaling processes and pathways. The
stepwise acquisition of genetic abnormalities leading up to invasive ductal adenocarcinoma
is now well characterized and includes mutations in KRAS2, inactivation of p16, p53, PDX1,
and SMAD4 [29].
Figure 4. Progression of normal epithelium to pancreatic cancer and genes involved in the pathogenesis of sporadic
pancreatic cancer.
Comprehensive genetic analysis of pancreatic cancer specimens demonstrated that the most
frequent genetic abnormality in invasive pancreatic adenocarcinomas is activation of KRAS2
oncogene, which was present in more than 90% of pancreatic cancers [28]. KRAS2 mutations
are thought to be acquired early in the development of pancreatic cancer as they are found in
a large number of ductal lesions and become more prevalent as these lesions progress to
invasive adenocarcinoma [27]. In addition to KRAS2 mutations, several other pathways in
cellular signaling have been found to be altered in 67-100% of the tumors. These pathways
include: TGF β, JNK, Integrin, Wnt/Notch, Hedgehog, control of G1/S phase transition,
apoptosis, DNA damage control, small GTPase, invasion, and homophilic cell adhesion [30].
Histologically, poorly formed glands are present in a dense fibrotic background within the
pancreatic parenchyma and sprinkled inflammatory cells. Some of the tumor cells might show
some mucin production. Perineural invasion is often seen and can help with the diagnosis in
well-differentiated tumors. Other features of malignancy include nuclear pleomorphism,
occasional large nuclei and multiple large nucleoli (Figure 5).
Figure 5. H&E stains of normal and adjacent ductal adenocarcinoma 40X (panel A). Panel B demonstrates invasive ad‐
enocarcinoma (100X). Perineural invasion is demonstrated in panel C.
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4. Clinical features
4.1. History
Currently there are no established screening tests for pancreatic cancer. The vague and
nonspecific symptoms in pancreatic cancer contribute to its delay in diagnosis. The location of
the tumor within the pancreas dictates some historical features and clinical presentation. The
stage of the disease is also important. Because most pancreatic tumors are located in the head
of the pancreas and present at an advanced stage, clinical findings suspicious for pancreatic
cancer must be rapidly addressed to exclude this lethal diagnosis.
Patients with lesions of the head of the pancreas present with painless jaundice and weight
loss, which might be accompanied with anorexia and weakness [31]. The frequency of
presenting symptoms in 1175 patients with adenocarcinoma of the pancreas was: 2/3 painless
jaundice, ½ weight loss, and about 1/3 abdominal pain [32]. Obstructive cholestasis might lead
to dark urine, light stools and pruritus. Distention of the pancreatic capsule causes vague
epigastric and/or back pain that poorly localizes to the location of the tumor. Obstruction of
the pancreatic duct or perineural invasion also causes pain, but this is less specific and poorly
localized. Ten percent of patients have symptoms attributed to cholelithiasis and will have
undergone recent cholecystectomy prior to the diagnosis of pancreatic cancer. Similarly,
obstruction of the pancreatic duct might lead to acute pancreatitis [13, 33]. Uncommonly, large
tumors might present with symptoms of duodenal obstruction such as nausea and vomiting
or symptoms associated with a gastrointestinal bleed [31].
Systemic manifestations are more usual in patients with lesions of the body and tail of the
pancreas such as weight loss and anorexia [31]. Constant pain is attributed to tumor invasion
of the celiac and mesenteric plexuses and occurs with advanced disease. Eight weeks is a
typical mean duration of symptoms. New-onset diabetes mellitus may be an initial presenting
symptom in patients with pancreatic cancer and glucose intolerance occurs in 15%-20% of these
patients. Depression, increased abdominal girth, and a history of panniculitis are rare, but
might accompany a diagnosis of pancreatic cancer [31, 34].
4.2. Physical examination
The physical examination for patients with pancreatic cancer is unyielding. Since two-thirds
of pancreatic adenocarcinomas occur in the head of the pancreas, the most common presenting
physical finding is evidence of obstructive cholestasis. Painless jaundice in an older patient
has been attributed a hallmark of physical findings necessitating careful exclusion of pancreatic
cancer. The examiner must investigate for signs of weight loss such as temporal wasting as
well as careful interrogation of lymph node basins [31].
Hepatomegaly, ascites or a palpable gallbladder (Courvoisier’s sign/law) may be present in
some patients with advanced pancreatic cancer. Courvoisier’s sign is more likely to be present
in patients with pancreatic cancer compared to calculi disease [35]. Physical findings in patients
with disseminated disease include supraclavicular lymphadenopathy (Virchow’s node).
However, pancreatic cancer usually does not metastasize to the supraclavicular nodes and
only a few cases have been reported [36]. Cutaneous metastasis in the periumbilical area (Sister
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Mary Joseph’s nodule) [37] and peritoneal seeding (Blumer’s shelf) are also rarely found with
pancreatic metastatic disease. Migratory thrombophlebitis (Trousseau’s sign), which is
evidence of intravascular thrombosis, may occur in patients with advanced pancreatic cancer
as well as other advanced cancers resulting from a hypercoagulable state from malignant
disease [38].
5. Staging
The AJCC staging system, based on the TNM stage, is most often used staging system for
pancreatic cancer. The tumor stage describes the size of the primary tumor, vascular structure
involvement and any direct extension of the tumor outside of the pancreas. The nodal stage
assesses the presence or absence of any regional lymph node involvement. The metastasis stage
describes the presence or absence of any distant disease (Table 1).
(a) Primary Tumor (T)
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ (includes lesions classified as PanInIII classification)
T1 Tumor limited to the pancreas, 2 cm or less in greatest dimension
T2 Tumor limited to the pancreas, more than 2 cm in greatest dimension
T3 Tumor extends beyond the pancreas but without involvement of the celiac axis or superior mesenteric artery
T4 Tumor invades the celiac axis or the superior mesenteric artery (unresectable primary tumor)
(b) Regional Lymph Nodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
(c) Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
(d) Anatomic Stage/Prognostic Groups
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1 N1 M0
T2 N1 M0
T3 N1 M0
Stage III T4 Any N M0
Stage IV Any T Any N M1
Table 1. TNM staging system for pancreatic cancer
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Common sites of metastatic disease often include the liver, peritoneal cavity, and lungs [39].
The anatomic staging roughly correlates with whether or not the tumor is resectable. Those
tumors with Stage IA to IIB are considered resectable. Tumors designated as Stage IV are
unresectable and those designated as stage III can be borderline resectable or unresectable. The
NCCN classification system which divides tumors into resectable, borderline resectable or
unresectable categories may be more applicable clinically [40].
6. Diagnostic evaluation
Routine laboratory analyses are rarely abnormal and if abnormal they lack specificity for a
diagnosis of pancreatic cancer. Evidence of extrahepatic obstruction may be revealed by
increased levels of serum alkaline phosphatase, bilirubin and gamma-glutamyl transferase
with possible mild elevations in hepatic aminotransferases [31]. Hypoalbuminemia and
anemia may be present in patients with advanced disease. Mild coagulopathy can be seen in
patients with obstructive jaundice. Poor flow of bile acids in the small bowel in these patients
decreases vitamin K absorption resulting in depletion of vitamin K dependent clotting factors
over time. Elevated pancreatic enzymes (elevated amylase and lipase) associated with acute
pancreatitis can rarely be the first manifestation of pancreatic cancer [41].
There are no accurate or reliable serum markers to aid in the diagnosis of pancreatic cancer.
Low sensitivity and cross-reactivity with other tumors have prevented the clinical use of
carcinoembryonic antigen (CEA), fetoprotein, and pancreatic oncofetal antigen in the diagno‐
sis of pancreatic cancer. Carbohydrate antigen 19-9 levels (normal <37 units/mL) has been the
most useful commercially available test. However, the sensitivity of CA 19-9 ranges from 70%
to 92% and the specificity is poor (68% to 92%) [42]. The accuracy of CA 19-9 in the diagnosis
of pancreatic cancer is excellent when combined with ERCP, abdominal CT, or abdominal US
[43]. High levels of CA 19-9 have been associated with poor prognosis and tumor unresecta‐
bility [43]. CA 19-9 is also useful in monitoring the response of therapeutic interventions. As
the CA 19-9 requires the presence of Lewis blood group antigen (a glycosyl transferase enzyme)
to be expressed, this serum marker is of no value in 10% of the population who is negative for
this antigen [44, 45].
7. Conventional imaging modalities
Imaging studies are essential in the management of pancreatic cancer. The most important
goal of imaging is to determine tumor resectability. Involvement of adjacent vessels (superior
mesenteric vein, portal vein, and superior mesenteric artery), nodal involvement and distant
metastatic lesions are paramount in selecting treatment options. The investigation of most
patients with pancreatic cancer generally begins with a right upper quadrant ultrasound to
evaluate jaundice.
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7.1. Abdominal ultrasound
Abdominal ultrasound (US) examination reliably detects extra-hepatic and intra-hepatic
ductal dilatation. However, accurate identification of a pancreatic mass may be compromised
by operator experience, bowel gas interference, or obesity, and does not provide information
regarding tumor involvement of the vascular structures or lymph node involvement. In
advanced disease, ascites and liver metastases (>1 cm) may be seen by abdominal US.
7.2. Computed Tomography
Computed tomography (CT) has been used routinely for evaluation of pancreatic cancer over
the last few decades. However, since the advent of triple phase (noncontrast, arterial, and
portal venous) helical multidetector row CT (MDCT) with thin cuts (1 mm slices) through the
pancreas along with coronal three dimensional reconstruction (pancreatic protocol), it has
become the gold standard initial test for the diagnosis and staging of all pancreatic cancers.
The sensitivity for lesions greater than 2 cm is 100% [46]. While the false positive rate is low,
it might occur in the setting of focal chronic pancreatitis or autoimmune pancreatitis. The
advantage of CT is its wide availability, non-invasive approach, non-operator dependent and
easily reproducible images. It is also deliberately used in conjunction with 18F-fluorodeoxy‐
glucose positron emission tomography (PET)/CT for surveillance imaging post treatment.
7.3. Endoscopic ultrasound
Endoscopic ultrasound (EUS) transmits high-frequency sound waves through the upper GI
tract to detect abnormalities in the pancreas (Figure 6). The accuracy of EUS is operator
dependent and it is not yet available at many community hospitals. At experienced centers,
EUS has been shown to have a similar (or better) sensitivity and specificity for the diagnosis
of pancreatic cancer to that of MDCT [47]. Being a dynamic test, it can distinguish subtle
abnormalities such as pancreatic duct strictures and small neuroendocrine tumors. Not
uncommonly, it can detect small (<1cm) pancreatic cancers, which would escape detection by
MDCT. EUS can also evaluate malignant as well as pre-malignant cystic lesions such as intra-
ductal papillary mucinous neoplasms with its characteristic findings of intramural nodules
and communication with the main pancreatic duct.
Figure 6. Malignant biliary obstruction from mass in head of pancreas causing CBD and PD dilation (double-duct sign) US
(A). MRCP in (B) Note the distended gallbladder, seen in patients with malignant biliary obstruction (Courvoisier’s sign)
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Due to the high sensitivity of EUS in detecting small lesions, it is widely used to screen patients
with familial pancreatic cancer or other hereditary syndromes [48]. EUS has the advantage of
allowing sampling of the tumor mass, regional nodes, liver lesions, ascites and malignant cyst
fluid, as well as assessing tumor resectability during diagnostic evaluation (Figure 7). In one
study, the sensitivity, specificity, and accuracy of EUS-FNA for diagnosis of a pancreatic
malignancy were 91%, 100%, and 92%, respectively. No mortalities were reported in this
analysis and morbidity was only 2% [49]. Recently, the EUS-FNA needles have been employed
to introduce sophisticated probes directly into the pancreatic lesions for diagnostic needs, as
well as deliver therapeutic approaches such as local injections of cytotoxic agents and probe
based application of radiofrequency ablation.
A.
B. C.
Figure 7. Mass in head of pancreas causing biliary obstruction (note both cystic duct and common bile duct are dilat‐
ed)-A; The portal Vein PV-B and PV confluence (C).
EUS is not without limitations in the evaluation of patients with pancreatic cancer. In some
cases pancreatic cancer might be indistinguishable from focal chronic pancreatitis (with or
without focus of ductal adenocarcinoma), pancreatic intraepithelial neoplasms-PanINs, and
patients with autoimmune pancreatitis. The ability of EUS alone in differentiating these from
malignant lesions can be challenging and thus a multimodality diagnostic evaluation becomes
necessary along with the history and physical exam findings. Tissue sampling for pathological
evaluation might also be challenging with EUS as fine needle aspiration provides scant aspirate
and core biopsies (by pro-core needles) might not give adequate histological architecture
needed to make an accurate diagnosis. Further limitations of EUS are the result of anatomical
constraints such as tumors located in the uncinate process because the acute angle of the
echoendoscope in the second portion of the duodenum makes this location challenging for
FNA sampling.
7.4. Endoscopic retrograde cholangiopancreatography
Endoscopic retrograde cholangiopancreatography (ERCP) has been used historically to allow
direct visualization of the duodenum and ampulla, as well as delineation of the biliary and
pancreatic ductal systems. ERCP may also be used to obtain “brush” samples for cytology and
intra-ductal biopsies in order to increase diagnostic yield, especially in situations where EUS-
FNA results are inconclusive. However, ERCP remains an invasive test with potential risks
such as post ERCP-pancreatitis, which might result from injecting contrast to delineate a
suspected malignant pancreatic duct stricture. Hence, the usefulness of ERCP as a primary
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diagnostic modality for pancreatic cancer has significantly decreased since the introduction of
endoscopic ultrasonography. Currently, ERCP is not favored as an initial test for the diagnosis
of adenocarcinoma of the pancreas. On the other hand, ERCP is generally reserved for
therapeutic indications such as palliating patients with obstructive jaundice from pancreatic
cancer with metastatic or locally advanced disease who are not candidates for resection. These
patients benefit from biliary sphincterotomy and/or stent placement (Figure 8). Routine
stenting of patients with resectable pancreatic cancer, however, has not shown clear benefits
in patients that might be considered candidates for resection as this might lead to unjustified
complications [50]. A new role of ERCP is evolving as a means to access the pancreatic duct
for endoscopic pancreatic imaging and therapeutics.
Figure 8. Malignant pancreatic stricture causing upstream pancreatic duct dilation. Note that the wire was advanced
into the bile duct during ERCP to place biliary stent for palliation of obstructive jaundice (A). Placement of metallic
biliary stent for palliation of obstructive jaundice in a patient with unresectable pancreatic cancer [fluoroscopic picture
(B); endoscopic picture (C)]
7.5. Magnetic resonance cholangiopancreatography
Magnetic resonance cholangiopancreatography (MRCP) is better than CT in outlining the
anatomy of biliary and pancreatic tree and can provide useful information in patients who
have suspected biliary or pancreatic strictures. It can also provide a road map for future
endoscopic therapy. MRI of the pancreas can provide valuable information about solid tumors
of the pancreas as well as cystic neoplasms, and is generally comparable to MDCT in deter‐
mining resectability (Figure 6) [51].
Centers without personnel experienced with EUS-FNA rely on percutaneous fine-needle
aspiration (FNA) of pancreatic masses to establish a diagnosis. CT-guided percutaneous FNA
performed by interventional radiologist carries a theoretical risk of malignant seeding of the
needle tract, but no convincing data has proven this theory conclusively. The CT guided
approach is technically easier for masses in the tail of the pancreas rather than the head. A
negative result on tissue diagnosis with a suspicious mass on CT scan does not preclude
surgical intervention. This approach can be helpful in patients who are considered poor
candidates for any endoscopic intervention due to underlying co-morbidities and individuals
who have unresectable disease.
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7.6. Exploratory laparoscopy
Reportedly, 20% to 40% of patients staged by CT, MRI, ERCP or EUS will have undetected
disseminated disease during exploratory laparoscopy. The use of laparoscopy has proponents
that span usefulness [52-54] to an entirely unnecessary procedure. The main argument against
its use emanates from the currently available non-invasive image modalities, which in the view
of some clinicians eliminates the need for a further invasive procedure [55]. Laparoscopic
exploration for patients with pancreatic lesions is best used selectively rather than routinely
and may have a larger role in resectable tumors of the body and tail of the pancreas [56;57].
Selective criteria for patients with pancreatic cancer include tumors larger than 3 cm, a CA 19-9
level above 100 U/ml, and questionable imaging findings.
8. EUS combined modalities
There has been recent interest in mucosal imaging (as discussed below), but none has yet been
accepted in the standard of care in diagnosing pancreatic cancer. Narrow band imaging
technology uses light of specific blue and green wavelengths to enhance the detail of certain
aspects of the surface of the mucosa. This technology has made it possible to visualize the wall
of the pancreatic duct with the help of a small catheter inserted into the pancreatic duct
(‘pancreatoscopy’) [58].
Optical endomicroscopy using a small diameter probe advanced into the pancreatic duct, at
the time of ERCP or EUS, allows real time microscopic imaging of the epithelial lining of the
pancreatic duct and pancreatic cyst wall. This allows direct high yield targeted tissue sampling
in the region of interest. Two modalities used in this fashion include confocal laser endomi‐
croscopy (CLE) [59;60] and high resolution microendoscopy [59;61]. On the other hand, optical
coherence tomography uses infrared light to scan areas beneath the mucosal lining of the duct
but the field of view is limited to only a few millimeters making evaluation of the entire
pancreatic duct difficult and time consuming [62].
During intraductal ultrasound (IDUS), a mini-ultrasound probe is advanced into the main
pancreatic duct to evaluate the wall of the pancreatic duct in indeterminate pancreatic
strictures. This allows diagnosis of early pancreatic cancers and outlines margins of IPMNs
before surgical resection [63;64]. IDUS is not widely used in United States due to the risk of
pancreatitis associated with the procedure and inability to obtain tissue for pathological
examination [65]. Another modality using EUS, contrast enhanced EUS, utilizes intravenous
contrast to highlight the echogenicity and enhancement of a lesion [66]. In a recent meta-
analysis, the pooled sensitivity of contrast-enhanced EUS for the differential diagnosis of
pancreatic adenocarcinomas was 94% (95% CI, 0.91-0.95), and the specificity was 89% (95% CI,
0.85-0.92) [67].
EUS elastography allows quantitative analysis of tissue stiffness and helps differentiate
pancreatic cancers from benign conditions such as chronic pancreatitis. In one study, the
sensitivity and specificity for detecting pancreatic malignancies was 100% and 92.9% respec‐
tively [68]. Three-dimensional reconstruction and spectrum analysis using EUS has shown
promising results, and will likely be used more often in the future [69].
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9. Novel diagnostic imaging modalities
Because pancreatic cancer might metastasize at an early stage, an ideal imaging modality is
one that would predict the biological behavior of the tumor. Understanding the molecular
aspects of pancreatic cancer has facilitated use of investigational modalities in this area.
Imaging agents such as peptides that bind to specific factors on the surface of pancreatic tumors
have been developed and include: plectin 1 (Plec 1), integrin αvβ6, cathepsin E and claudin-4
[70-73]. Early studies have shown promising results, but more work is needed before routine
clinical use.
A similar approach, but by interrogating normal tissue has also been investigated. Montet et
al. demonstrated that as pancreatic tumors do not express receptors for bombesin, a bombesin
peptide-coupled nanoparticle (BN-CLIO[Cy5.5]) can be used to image normal pancreas and
hence, differentiate it from pancreatic tumors [74]. Similarly, a novel concept of microbubbles,
small gas –filled microspheres, has been used in preliminary studies to image the peri-tumoral
vasculature with the assistance of ultrasound. Moreover, this technology can also be used as
a vehicle to deliver anti-cancer therapies [75].
10. Treatment
10.1. Surgical intervention
Surgery offers the only possibility for long term survival, however the majority (>85%) of
patients with pancreatic cancer will present with unresectable or metastatic disease [76].
Removal of all disease offers the patient the only chance of long-term survival. Those who
undergo surgical resection have a disappointing ~20% 5-year survival. Over the years it has
become clear that the indications for surgical intervention have been substantially widened.
Typically, the current criteria dictates possible resection for tumors stage I-A to II-B [77]. There
are no randomized trials that assess resectability criteria to guide surgical intervention. In the
absence of controlled trials, the best recommendations emanate from consensus guidelines [40,
78, 79]. It is practical to classify pancreatic tumors into one of three categories following
diagnostic imaging [77]:
i. Resectable Tumors: These are tumors localized to the pancreas. In this case, there is
no evidence of SMV or portal vein involvement of any kind. A plane of dissection
indicated by a fat pad between the SMA, celiac axis, and hepatic artery and the
pancreas has to be identified by CT scan as well as absent involvement of the SMV
and portal vein [40, 78]. These patients should proceed with surgical intervention.
ii. Borderline Resectable Tumors: There is a dynamic criteria for resection of these
tumors that continues to change based on the ability of specialized centers to perform
complex arterial/venous/portal resection and reconstruction [79]. These tumors
include those that have (A) Severe SMV-portal impingement (unilateral or bilateral),
(B) SMA/celiac artery involvement, but less than 180°, (C) Hepatic artery involvement
with the possibility of reconstruction, and (D) SMV occlusion or involvement with
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the possibility of reconstruction [40, 77]. These patients should undergo surgical
intervention at the discretion of highly specialized pancreatic cancer centers, undergo
neoajuvant treatment, and/or enrollment in clinical trials.
iii. Unresectable Tumors: These are tumors in which distant or extensive lymph node
metastatic disease has been identified. Involvement of vasculature beyond resection
or malignant ascites are also considered contra-indications for resection (i.e. major
venous thrombosis of the portal vein or SMA that extends for several centimeters or
circumferential encasement of the SMA) [78]. Resectability is best determined
preoperatively rather than intraoperatively. These patients are candidates for
chemotherapeutic interventions and enrollment in clinical trials as well as palliative
interventions depending on degree of the disease.
According to a consensus statement by the American Hepato-Pancreato-Biliary Association,
tissue obtained via EUS guided FNA is only required prior to surgery if neoadjuvant chemo‐
radiation is indicated. However, if there is sufficient evidence for pancreatic adenocarcinoma
based on history, physical exam, and diagnostic modalities; no tissue is required in good
surgical candidates prior to surgical intervention [78].
11. Surgical intervention for tumors of the pancreatic head
Extirpation of pancreatic tumors at the head of the pancreas require pancreatic and duodenal
resection as well as common bile duct re-implantation with reconstruction. The pacreatico‐
duodenectomy procedure (Figure 9) was first described in 1909 by Walter Kausch. Twenty six
years later, the success with the procedure in three patients was reported at the American
Surgical Association by Allen O. Whipple and Parson. The pancreaticodudenectomy proce‐
dure then became widely performed and it is commonly referred to as the Whipple procedure.
Although, it’s original description was a two-stage operative approach, it was rapidly modified
[80]. The commonly known one-stage Whipple operation is credited to Trimble’s group from
John Hopkins in 1941 [81]. The drastic increase in the number of operations performed today
is represented by the experience at Mass General where between 1940 and 1950, twenty
pancreaticoduodenectomies were performed; while, between 2005-2011 813 were described
(~125 per year) [82].
Technical considerations for standard pancreaticoduodenectomy (PD) have been reviewed
extensively [83]. The proposed lines of resection are shown in (Figure 9). The general explo‐
ration of the abdomen includes careful inspection of the peritoneal surfaces and liver for
metastases, which can be more accurately determined by intra-operative liver ultrasonogra‐
phy. Suspicious lymph nodes need to be submitted for frozen section histology to evaluate for
metastatic disease. The presence of peritoneal implants and liver metastases render the patient
incurable. Similarly, histologically proven metastases in lymph nodes accessible during the
initial abdominal exploration makes the chance of cure highly remote.
Following abdominal exploration, the right colon is mobilized and retracted medially; a
technique known as the Cattell-Braasch maneuver. The lesser sac is entered and posterior
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attachments of the stomach are divided. The superior mesenteric vein is identified by tracing
the middle colic vein proximally, or after Kocherization by following the sweep of the
duodenum medially. The gallbladder is mobilized and the common hepatic duct and gastro‐
duodenal arteries are divided. These maneuvers allow exposure of the anterior surface of the
portal vein. The portal vein and superior mesenteric vein are carefully separated from the
overlying pancreas. The stomach (or duodenum in cases of pylorus-preserving pancreatico‐
duodenectomy [PPPD]), small bowel, and pancreas are then divided sequentially. The
uncinate process is liberated from its retroperitoneal attachments to complete the dissection.
Gastrointestinal continuity is re-established by a pancraticojejunostomy (or pancreaticogas‐
trostomy), choledocojejunostomy, and gastrojejunostomy (or duodenojejunostomy in the case
of PPPD). Anastomoses are done in sequence: pancreas, then bile duct, then stomach (or
duodenum in the case of PPPD) (Figure 9).
Figure 9. Lines of resection of the typical pancreaticodoudenectomy. Reconstruction is performed in order from A to C.
PPPD is a modification of the standard Whipple procedure in which the entire stomach,
including the pylorus, and 2 cm to 3 cm of the duodenal cuff, are preserved. This modification
retains the entire stomach as a reservoir and may prevent the development of postgastrectomy
syndromes, marginal ulceration, and enterogastric reflux. PPPD is touted to result in shorter
operative times, less blood loss, and fewer transfusions. PPPD was first described by Dr.
Warshaw in 1981 and has been the largest variation of the procedure since the one-stage
approach was introduced in clinical practice [83]. However, delayed gastric emptying without
much further benefit has led to a change back to the gastrojejunostomy approach in some
centers, but this remains a point of controversy [84, 85].
Pancreaticojejunostomy may be performed as an end to-end “dunking” procedure, an end-to-
side anastomosis between pancreas and jejunum, or an end-to-side duct-to-mucosa anasto‐
mosis. A duct-to mucosa anastomosis may be performed over a stent and left in place for
pancreatic ducts less than 5 mm. The primary theoretical advantage of duct-to-mucosa
pancreaticojejunostomy is long-term patency. Pancreaticogastrostomy (PG) is performed in
an end-to-side fashion. There is no evidence that the type of pancreatic-enteric anastomosis
affects the rate of pancreatic fistula. Because pancreatic fistulas remain the most serious
complication of the operation, a pancreaticogastrostomy (PG) instead of a pancreaticojejunos‐
tomy (PJ) has been performed by some surgeons. Randomized controlled trials (n=3) have not
shown a difference in complications with these two approaches. However, thirteen non‐
randomized observational clinical studies have been in favor of PG [86]. Further studies are
needed to clarify these findings.
Cancer Treatment14
The biliary and pancreatic anastomoses are drained and jejunostomy (for feeding) and
gastrostomy (for decompression) tubes are placed prior to closure. Routine placement of
feeding and decompression tubes is paramount in the postoperative management of patients
following a pancreaticodudodenectomy.
Total pancreatectomy for pancreatic cancer is rarely performed. Total pancreatectomy had
been proposed to obtain superior tumor margins and provide a more extensive lymph node
dissection. In practice, total pancreatectomy is associated with increased postoperative
mortality and no change in survival compared to standard pancreaticodudenectomy. Postop‐
erative diabetes is extremely difficult to manage in patients undergoing total pancreatectomy.
Similarly, extensive lymph node dissection does not improve survival and leads to a higher
complication rate [87].
Fifteen percent of pancreatic adenocarcinomas occur in the body and the tail of the pancreas.
Because these tumors typically do not cause biliary obstruction, its diagnosis is not made until
the disease is advanced and unresectable. Only 5% to 7% of individuals with adenocarcinoma
of the body or the tail of the pancreas undergo resection and their survival is much worse
compared to patients with adenocarcinoma of the head of the pancreas [77]. Distal pancrea‐
tectomy with splenectomy is reserved for rare instances when the tumor located in the body
or the tail of the pancreas is resectable.
11.1. Laparoscopic Pancreaticoduodenectomy
While the formidable Whipple remains one of the most complex abdominal operations
performed today, at some centers it has become common practice where several open opera‐
tions are performed in a week at Johns Hopkins or Mass General. With the continued ad‐
vancement in laparoscopic technique and popularity of this approach to surgical intervention,
there has been a rapid acceptance of more advanced laparoscopic approaches to patients with
cancer. The first total laparoscopic pancreaticoduedenectomy was described by Gagner and
Pomp in 1994 and constitutes one of the most advanced laparoscopic procedures today [88;89].
Between the time it was first described to 2009, 146 laparoscopic pancreaticoduodenectomies
were performed worldwide. A large series has been reported by Palanivelu and colleagues
which included 45 pancreaticoduodenectomies between 1998 and 2010 of which 18 were for
pancreatic adenocarcinoma [90]. Another large report from the U.S. included 65 cases of
laparoscopic pancreaticoduodenectomy and documented a morbidity of 42% and a mortality
of 1.5% [89]. A more recent review reported 10 case series totaling 150 totally laparoscopic
pancreaticoduodenectomies. In this review, mortality and morbidity have been comparable
to the open approach. Operative time for this cohort has been 483 minutes and length of
hospital stay 14.1 days [91]. The leading authors on these studies have concluded that the
laparoscopic Whipple is feasible and safe. However, in the absence of controlled trials this
approach remains experimental.
11.2. Robotic pancreaticoduodenectomy
The first pancreaticoduodenectomy was described in 1909 by Kausch. In 1935 AO Whipple
described three successful cases via a two-stage approach [80]. One-stage Whipple was
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introduced in 1941 by Trimble [81]. No major variations occurred in technique until preser‐
vation of the pylorus was introduced by Warshaw in 1981 [85]. These changes in operative
technique were not as radical as the introduction of the minimally invasive approach. The
laparoscopic pancreaticoduodenectomy was introduced by Gagner and Pomp in 1994 [88].
Almost 100 years later, the first human robotic surgery was described by Himpens in 1997 [92]
and the first robotic pancreaticoduodenectomy is credited to Giulianotti in 2000 [93]. While
several limitations still exist, robotic surgery is the most innovative technology brought to the
operating room in the last century.
A recent systematic review of the robotic approach demonstrated that up to date, 203 patients
have had an intention to treat approach to a pancreaticoduodenectomy [94]. While the
technical approach is wide and not clearly defined, the number of reported cases appears to
be increasing over the past few years. In Cirocchi’s review, the conversion rate was 14%, overall
morbidity 58% and reoperation occurred in 7.3% of the cases [94]. Totally robotic technique
has been reported by several surgeons [93;95-98]. While oncologic operations (R0) have been
performed with similar morbidity and mortality to the open Whipple, the innovative nature
of this approach makes it highly experimental and should only be undertaken in specialized
centers. Similarly, cost analysis must be addressed in subsequent studies.
12. Outcomes
In the United States, there has been a substantial increase in the number of pancreaticoduo‐
denectomies performed. The average age of patients undergoing surgical intervention has also
increased from 1991 to 2005. Similarly, more patients with a higher index of comorbidities
underwent Whipples during this time. In spite of this, perioperative morbidity remained
unchanged (53%) and 30-day mortality decreased from 6% to 3% in this cohort of patients [1].
The mortality rate in high volume centers performing pancreaticoduodenectomies is 2-4%
[99].  However,  perioperative morbidity remains substantially high (15% to 50%) even at
high  volume  centers  [100].  In  patients  undergoing  resection  for  cure  and  treated  with
neoadjuvant chemoradiation, the 5-year survival is still disappointingly low (10% to 20%)
[101-106]. In a study using the Surveillance, Epidemiology, and End Results-Medicare data
inclusive of  2,461 patients  investigating outcomes and use of  adjuvant  therapy between
1991 and 2005 in the USA, the median survival of patients treated for cure was 14 months,
the  1-,  3-,  and  5-  year  survival  was  53.2%,  19.7%,  and  12.6%,  respectively.  This  study,
demonstrated that  the use of  adjuvant  chemoradiotherapy led to  a  2  month increase in
overall survival [1]. A study from Johns Hopkins examining temporal variation in morbid‐
ity  and  mortality  following  pancreaticoduodenectomy  found  a  magnificent  decrease  in
mortality  to  4%  (1981-1986)  from  24%  (1969-1980)  with  an  accompanying  decrease  in
morbidity from 59% to 36% during the same periods. The 5-year survival in patients with
pancreatic cancer was 18% [107]. Thus, while the number of patients undergoing pancrea‐
ticoduodenectomy  has  increased  with  a  variable  decrease  in  complications,  the  overall
mortality has not improved in most high volume centers [108].
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13. Morbidity
Postoperative complications occur in 25-50% of patients following this operation. Delayed
gastric emptying, even with standard definitions by the International Study Group of Pancre‐
atic Surgery, occurs in a wide range of 14% to 45% and constitutes the most common compli‐
cation following pancreaticoduodenectomy [109-111]. Erythromycin or metoclopramide may
reduce the incidence of gastric emptying by only 37% [112]. Thus, a jejunostomy tube for
prolonged postoperative feeding as well as a gastrostomy tube for postoperative decompres‐
sion should be routinely employed during pancreaticoduodenectomy.
Pancreatic fistula (defined as the output of more than 50 cc of amylase-rich fluid) accompanies
5%-30% of cases [113-117] and is directly responsible for up to 20% of postoperative deaths
[115;117], which constitutes the most serious complication of pancreaticoduodenectomy.
Pancreatic fistula indicates disruption of the pancreatic-enteric anastomosis and occurs at the
same rate regardless of anastomosis (i.e. pancreaticogastrostomy vs. pancreaticojejunostomy),
modified drainage strategies, or somatostatin administration [118].
Disruption of biliary and gastric anastomoses are rare and less serious. Patients with pancreatic
fistula may be completely asymptomatic if it is a controlled fistula and the output is well
captured by the drain. These patients do well with a clear liquid diet, enteral nutrition through
a jejunostomy tube, or parenteral nutrition. A CT scan should be performed to exclude
abdominal fluid collections. The benefits of somatostatin in this setting are unclear. Diet may
be progressively advanced as output decreases. Eighty percent of patients can be managed
conservatively. An additional 10%-15% of patients with this complication respond well to
percutaneous drainage.
Patients with sepsis or hemorrhage related to pancreaticoenteric anastomotic disruption
necessitate immediate and aggressive intervention. Septic patients who do not respond to
aggressive medical management within 48 hours should be explored. Hemorrhage associated
with pancreatic fistulas can be managed with angiographic embolization. Patients who require
operative exploration and have diffuse retroperitoneal hemorrhage and necrosis require
completion pancreatectomy. The rare cases of hemobilia and hemopancreaticus are best
diagnosed and treated angiographically.
Endocrine pancreatic function is rarely impaired and diabetes is unusual following pancrea‐
ticoduodenectomy. Exocrine pancreatic function, on the other hand, is affected to various
degrees and in severe cases may require lifelong exogenous enzyme supplementation.
14. Neoadjuvant therapy
There are no randomized controlled trials that compare neoadjuvant to adjuvant therapy for
patients with resectable disease. Potential benefits of neoadjuvant therapy include identifying
those patients with occult metastatic disease thereby selecting patients who would probably
not benefit from surgery. Another potential benefit is avoiding delay in chemotherapy for those
patients who have postoperative complications or prolonged recovery. Conversely, the
Current Concepts in Pancreatic Cancer 17
response rates to neoadjuvant therapy are low (9-12%) which may allow for disease progres‐
sion with the delay of surgery [119;120]. Since there is stronger data supporting adjuvant
therapy, most centers prefer this approach over neoadjuvant therapy for patients with
resectable disease.
Patients with borderline resectable cancer or locally advanced disease can be treated with
neoadjuvant therapy with the goal of down-staging allowing for possible resection. Currently,
there is no defined optimal neoadjuvant therapy for this population of patients supported by
randomized controlled trials. The National Comprehensive Cancer Network recommends that
patients with borderline resectable disease undergo a laparotomy followed by resection if
possible or upfront neoadjuvant therapy. Available options for neoadjuvant therapy include
FOLFIRINOX, gemcitabine, gemcitabine-based combination therapy, capecitabine or contin‐
uous infusion 5-FU [40]. It is suggested that chemoradiation should be reserved for patients
who do not develop metastatic disease while receiving chemotherapy [40]. A meta-analysis
showed that 31.6% of patients with initially borderline/unresectable tumors treated with
neoadjuvant therapy were able to undergo resections. These patients had a median survival
of 22 months which appears comparable to those patients with initially resectable disease [120].
15. Adjuvant therapy
Only about 15-20% of cases of pancreatic cancer are considered resectable. Even after resection
the prognosis is poor with 5-year survival rates approximating 20% [121]. Systemic chemo‐
therapy and radiation have been used adjuvantly to improve the survival rates. However the
optimal choice of adjuvant therapy remains quite controversial. There have been several phase
III studies evaluating therapy in the adjuvant setting; these are summarized in Table 2. The
GITSG Trial compared concurrent 5-FU based chemoradiation with observation alone after
resection. This study was closed early due to slow accrual and only had 49 patients enrolled
at the time of analysis. The GITSG Trial showed an improved survival benefit (median survival
20 months vs. 11 months, p=0.03) favoring the concurrent chemoradiation group [122]. The
GITSG study was followed up by the EORTC study which was similar in design, comparing
5-FU based concurrent chemoradiation to observation. The EORTC study demonstrated no
survival advantage with adjuvant therapy. The 2-year survival was 26% vs. 34% for the
observation and treatment arms respectively; this difference was not statistically significant
[123]. The ESPAC-1 Trial had a 2 x 2 factorial design in which they compared concurrent
chemoradiation, chemotherapy, chemoradiation followed by chemotherapy or observation.
This study was only powered to compare the chemotherapy vs. no chemotherapy group and
the chemoradiotherapy vs. no chemoradiotherapy group. The results showed a statistically
significant improved median survival for those patients who received chemotherapy (20.1
months) compared to those patients who did not receive chemotherapy (15.5 months).
Interestingly this study demonstrated a worse median survival for patients receiving chemo‐
radiotherapy (15.9 months) compared to those patients that did not receive chemoradiother‐
apy (17.9 months) [124]. Three trials were done evaluating the efficacy of gemcitabine. The
CONKO-001 trial compared adjuvant gemcitabine to observation. The trial showed a statisti‐
cally significant improvement in median disease free survival of 13.4 months (gemcitabine
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arm) compared to 6.9 months (observation arm). There was no difference in overall survival,
but this was attributed to the fact that most patients in the observation arm received gemcita‐
bine on relapse [104]. Two trials compared 5-FU with gemcitabine. In the RTOG 9704 study
all patients received concurrent 5-FU based chemoradiation with either 5-FU or gemcitabine
given before and after. The ESPAC-3 trial compared adjuvant 5-FU to gemcitabine without the
use of radiation. Both of these studies showed no survival advantage for one arm over the
other. However in the RTOG 9704 study those patients stratified to the gemcitabine arm did
have a greater proportion of T3 or T4 disease which may account for no improvement in
survival. The ESPAC-3 trial did demonstrate that gemcitabine was associated with fewer
adverse events [104;124]. The treatment practice for these patients can be quite variable. Some
advocate for adjuvant chemotherapy alone without radiotherapy based on the EORTC and
ESPAC-1 trials. Others continue to advocate for radiotherapy given the high risk of local failure
and the benefit seen in the GITSG study. The dose of radiation given in these studies would
be considered suboptimal by today’s standards which the supporters of radiotherapy argue
explains why the benefit was not seen in the EORTC and ESPAC-1 studies.
Trial Intervention Results Conclusions
GITSG
Concurrent CRT (5-FU) -
>maintenance 5-FU
Observation
Median Survival
20 mos vs. 11 mos
P=0.03
-Survival benefit of CRT
followed by maintenance chemo
EORTC Concurrent CRT (5-FU, 40Gy)Observation
2-yr Survival
34% vs. 26%
P=0.099
-No statistically survival benefit
observed
ESPAC-1
Observation
Chemotherapy (5-FU/L)
CRT (5-FU/L)
CRT -> Chemo (5-FU/L)
5-yr Survival
10% (CRT) vs. 20% (no CRT)
P=0.05
21% (chemo) vs. 8%(no chemo)
P=0.009
-Adjuvant chemo has a survival
benefit
-CRT with a deleterious effect
on survival
RTOG 9704 5-FU pre and post CRTGemcitabine pre and post CRT
Median Survival
17.1 mos vs. 20.5 mos
P=0.08
-No improvement of
Gemcitabine over 5-FU
CONKO-001 GemcitabineObservation
Median DFS
13.4 mos vs. 6.9 mos
P<0.001
Median Survival
22.8 mos vs. 20.2 mos.
P=0.005 (update from 2008)
-Gemcitabine improved DFS.
-Updated survival data shows a
benefit with Gemcitabine
ESPAC-3 5-FUGemcitabine
Median Survival
23 mos vs. 23.6 mos
P=0.39
Serious Adverse Events
14% vs. 7.5%
P<0.001
-No difference in survival
-Gemcitabine associated with
less toxicity
Table 2. Phase III Adjuvant Therapy Trials
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16. Metastatic disease
Systemic therapy for metastatic pancreatic cancer is aimed at minimizing disease-related
symptoms and prolonging survival. For several years the standard of care was 5-fluorouracil
(5-FU)-based combinations with an observed survival benefit over best supportive care. The
median survival with 5-FU-based combinations on average approximates 6 months versus 3
to 4 months with best supportive care [125]. In 1996, gemcitabine was approved for treatment
of metastatic pancreatic cancer after a phase III trial demonstrated a clinical benefit response
of 23.8% for those in the gemcitabine group compared to only 4.8% in the 5-FU group
(P=0.0022). Secondary endpoints evaluated in the trial included survival rate, which at 12
months was 18% for the gemcitabine arm and 2% for the 5-FU arm [126]. Several gemcitabine-
based combinations have been investigated with the goal of further improving its therapeutic
efficacy. Sun et al. performed a meta-analysis investigating gemcitabine-based combinations
compared with gemcitabine monotherapy. The meta-analysis found that combination therapy
provided a modest 1-year overall survival with a RR of 0.90 (P=0.04). However, this benefit
with combination therapy was associated with more grade 3-4 toxicities including vomiting,
diarrhea, neutropenia, anemia and thrombocytopenia. Based on subgroup analyses patients
with a good performance status appeared to derive the most survival benefit from combination
therapy [127]. The combination of gemcitabine and erlotinib was compared to gemcitabine
alone in a phase III trial where a very modest improvement in median survival was observed
(6.24 months vs. 5.91 months). In this study, 53% of samples were classified as EGFR positive.
Interestingly EGFR status did not have any association with response or disease stability [128].
In 2011, Conroy et al. reported results of a randomized controlled trial of FOLFIRINOX
compared to gemcitabine. The combination chemotherapy regimen improved the objective
response rate from 9.4% in the gemcitabine group to 31.6% in the FOLIRINOX group (P<0.001).
Median survival was also improved to 11.1 months in the FOLFIRNOX arm compared to 6.8
months in the gemcitabine arm (P<0.001). The combination chemotherapy, as seen with prior
combination regimens, was associated with more adverse events [129]. Recently, the combi‐
nation of nab-paclitaxel and gemcitabine was approved for first-line therapy in metastatic
adenocarcinoma of the pancreas. Objective response rates were 23% and 7% in the nab-
paclitaxel plus gemcitabine arm and single agent gemcitabine arms, respectively (P<0.0001).
Progression free survival was also improved with a median PFS of 5.5 months in the combi‐
nation arms compared with 3.7 months in the single agent arm (P<0.0001). There was also an
observed median survival benefit of 8.5 months for the nab-paclitaxel plus gemcitabine arm
while the single agent gemcitabine arm only had a median survival of 6.7 months (P<0.0001)
[130] (Table 3).
17. Palliation
Palliation of pancreatic cancer patients may be the goal of operative exploration or may
result  from  operative  findings  indicating  unresectablility.  Palliation  can  be  performed
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operatively and nonoperatively and this decision should be individualized depending on
the  overall  status  of  the  patient.  Whether  palliation  is  accomplished  operatively  or
nonoperatively, relief of obstructive jaundice, duodenal obstruction, and back pain are the
primary goals. About 65% to 75% of patients with pancreatic cancer will develop symp‐
toms of obstructive jaundice [131]. In patients with obstructive jaundice endoscopic biliary
stenting and surgical  biliary bypass are palliative options.  Endoscopic biliary stenting is
associated  with  lower  complication  rates  and  shorter  hospital  stays  while  maintaining
similar efficacy and overall survival compared with surgical bypass [132]. In the event that
endoscopic  management  is  not  successful,  external  biliary  drainage  can  be  attempted.
Duodenal  obstruction develops  in  about  15% to  20% of  patients  with  pancreatic  cancer
[133].  Traditionally duodenal obstruction had been palliated with gastrojejunostomy, but
Study Intervention Results
Burris et al. 1997
Phase III
Gemcitabine
5-FU
Clinical Benefit Response
23.8% vs. 4.8%
P=0.0022
Median Survival
5.65 mos vs. 4.41 mos
P=0.0025
Moore et al. 2007
Phase III
Gemcitabine + Erlotinib
Gemcitabine + Placebo
Median Survival
6.24 mos vs. 5.91 mos
P=0.038
Sun et al. 2012
Meta-analysis
Gemcitabine monotherapy
Gemcitabine combination therapy
Objective Response Rate
RR, 0.72; 95% CI: 0.63-0.83
P<0.001
1-yr Overall Survival
RR, 0.90; 95% CI: 0.82-0.99
P=0.04
Conroy et al. 2011
Phase III
FOLFIRINOX
Gemcitabine
Median Survival
11.1 mos vs. 6.8 mos
P<0.001
Median PFS
6.4 mos vs. 3.3 mos
P<0.001
Von Hoff et al. 2013
Phase III
Nab-Paclitaxel + Gemcitabine
Gemcitabine
Median Survival
8.5 mos vs. 6.7 mos
P<0.0001
PFS
5.5 mos vs. 3.7 mos
P<0.0001
Table 3. Selected studies for palliative chemotherapy in the metastatic setting
Current Concepts in Pancreatic Cancer 21
with  data  showing  similar  efficacy  with  enteral  stents,  improved  cost-effectiveness  and
shorter hospitalizations this option has become a viable alternative [134].
Most patients with pancreatic cancer, at some point in their disease course, will experience
severe cancer-related pain. This pain can be a severely debilitating symptom leading to poor
quality of life and decreasing performance status. In addition to systemic analgesics, regional
celiac plexus nerve block is effective at alleviating pain [135]. In general, endoscopic palliative
measures are preferred for those patients with known unresectable disease or those with a
poor performance status. For patients who are discovered to have unresectable or metastatic
disease on open exploration and expected to have a life expectancy of at least 3 to 6 months
operative palliative measures (choledochojejunostomy, gastrojejunostomy and intraoperative
chemical splanchnicectomy) can be considered for symptoms of obstruction and pain [136].
18. Conclusions
Multiple diagnostic and therapeutic modalities in the evaluation and treatment of pancreatic
cancer have not resulted in a meaningful survival advantage in patients with pancreatic cancer.
This dismal performance is primarily related to the inherent aggressive tumor biology of
pancreatic adenocarcinoma. Early diagnosis and curative resection, when possible, holds
promise for better survival but surgery in itself carries a definite morbidity and mortality, even
in specialized centers. Hence, pancreatic adenocarcinoma should be managed at high volume
centers in a multi-disciplinary setting and in light of proposed guidelines, until better treatment
options are available in the future.
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